What is the recommended diagnostic work‑up and treatment for a patient with acute anemia of unknown cause and a bone‑marrow biopsy showing a hypercellular marrow with trilineage maturation, erythroid hyperplasia, and mild megakaryocytic expansion?

Diagnostic Work-Up and Management for Acute Anemia with Hypercellular Marrow

The priority is to systematically exclude reversible causes of anemia before considering myelodysplastic syndrome (MDS), which requires comprehensive laboratory testing, cytogenetic analysis, and potentially flow cytometry, followed by observation with repeat bone marrow examination if initial findings are inconclusive.

Initial Mandatory Diagnostic Work-Up

The bone marrow findings of hypercellular marrow with trilineage maturation and erythroid hyperplasia are non-specific and can occur in both reactive conditions and clonal disorders like MDS. Before diagnosing MDS, you must systematically exclude all reversible causes of cytopenia and dysplasia 1.

Essential Laboratory Testing

Complete the following mandatory blood tests 1:

Nutritional/Metabolic:

• Vitamin B12 (cobalamin) and RBC folate/serum folic acid
• Iron studies: serum iron, total iron binding capacity, ferritin
• Lactate dehydrogenase, bilirubin, haptoglobin (to assess hemolysis)
• Reticulocyte count

Infectious Screening:

• HIV testing
• Parvovirus B19 antibodies (particularly important with erythroid hyperplasia)
• Cytomegalovirus
• Hepatitis B and C (especially if transfusion-dependent)

Other Critical Tests:

• Flow cytometry for paroxysmal nocturnal hemoglobinuria (PNH) clone
• Serum erythropoietin level

Mandatory Bone Marrow Studies

You must obtain cytogenetic analysis—this is non-negotiable 1, 2. Cytogenetics are mandatory for:

• Detecting clonal chromosomal abnormalities (del(5q), del(20q), +8, -7/del(7q))
• Establishing definitive MDS diagnosis
• Prognostic stratification

Additional recommended bone marrow studies 1:

• Flow cytometry immunophenotyping to detect abnormalities in erythroid, myeloid, and megakaryocytic compartments
• Prussian blue stain to identify ring sideroblasts (≥15% required for certain MDS subtypes)
• Assessment of blast percentage (must be <20% for MDS; ≥20% indicates acute leukemia)
• Reticulin staining to evaluate fibrosis

If standard cytogenetics fail, FISH analysis is recommended for targeted chromosomal abnormalities 1.

Clinical History Requirements

Obtain detailed exposure and medication history 1:

• Prior chemotherapy, radiation therapy, radioimmunotherapy
• Occupational or hobby benzene exposure
• Complete medication list (many drugs cause cytopenias)
• Alcohol intake and smoking history
• Bleeding/bruising tendency
• Recent infections

In younger patients, specifically assess for inherited bone marrow failure syndromes (Fanconi anemia, telomere disorders) through family history and consider genetic testing if clinically indicated 1.

Diagnostic Algorithm and Timeline

If Cytogenetics Show MDS-Associated Abnormalities:

• Diagnosis can be established even without robust morphologic dysplasia 2
• Proceed to risk stratification and treatment planning

If Cytogenetics Are Normal or Non-Informative:

The diagnosis becomes more challenging. Look for these decisive criteria 2:

1. Dysplasia ≥10% in ≥1 major bone marrow lineage
2. Blast count 5-19%
3. Ring sideroblasts ≥15% of erythroid precursors

Critical caveat: If you see only mild dysplasia, no increased blasts, <15% ring sideroblasts, and normal cytogenetics, do not rush to diagnose MDS 1. Instead:

• Observe for 6 months with repeat bone marrow examination (or 2 months if bilineage dysplasia is present) 2
• These patients typically have mild cytopenia and low risk of rapid progression
• Repeated examinations may be needed weeks, months, or even years apart to establish diagnosis 1

Common Pitfalls to Avoid

1. Megaloblastic anemia mimics MDS: Vitamin B12/folate deficiency causes hypercellular marrow with erythroid hyperplasia and can show dysplastic features. Always check and correct nutritional deficiencies first 3.

2. PNH can present similarly: Flow cytometry for PNH clone is essential, especially in younger patients with hypoplastic features 2.

3. Parvovirus B19 causes erythroid hyperplasia: Test for this, particularly with acute anemia and erythroid expansion 1.

4. Drug-induced cytopenias: Many medications cause reversible bone marrow changes that mimic MDS.

5. Don't rely on flow cytometry blast counts for prognosis: Morphologic blast percentage by an experienced hematopathologist is required for accurate risk stratification 2.

Referral and Monitoring

All newly diagnosed patients should be evaluated at a center with specific hematologic competence to ensure comprehensive diagnostic approach 1. This is particularly important given the complexity of distinguishing MDS from reactive conditions.

For patients under observation without definitive diagnosis:

• Monitor blood counts regularly
• Assess for clinical deterioration
• Repeat bone marrow examination as clinically indicated
• Document stability of cytopenias over time (stable cytopenia for at least 6 months supports MDS diagnosis) 2

Treatment Considerations

Treatment decisions cannot be made until:

1. Reversible causes are excluded or corrected
2. Definitive diagnosis is established
3. Risk stratification is completed (if MDS is confirmed)

The hypercellular marrow with erythroid hyperplasia suggests active but ineffective hematopoiesis, which could represent early MDS, but premature treatment before excluding reversible causes can lead to unnecessary toxicity and missed opportunities for simple interventions (like B12 supplementation).